Should patients with hypertension receive antithrombotic therapy?

Related Experiment Videos

G Y Lip1, E Edmunds, D G Beevers

  • 1Haemostasis, Thrombosis and Vascular Biology Unit, University Department of Medicine, City Hospital, Birmingham, UK. G.H.Y.Lip@bham.ac.uk

Journal of Internal Medicine
|April 4, 2001
PubMed

Insights

Hypertension increases thrombosis risk, leading to serious complications. Antithrombotic therapy, including aspirin, can help prevent these events, but bleeding risks must be considered, especially in low-risk patients.

Area of Science:

  • Cardiovascular Medicine
  • Hematology
  • Pharmacology

Background:

  • Hypertension is linked to major complications like coronary heart disease, ischemic strokes, and peripheral vascular disease, primarily due to thrombosis.
  • Hypertension contributes to a prothrombotic state by affecting hemostasis, platelets, and endothelial function, aligning with Virchow's triad.
  • Antithrombotic therapy is a potential strategy to mitigate thrombosis-related complications in hypertensive individuals.

Purpose of the Study:

  • To evaluate the role of antithrombotic therapy in preventing thrombosis-related complications of hypertension.
  • To assess the benefits and risks of aspirin use in hypertensive patients for both primary and secondary prevention.

Main Methods:

  • Review of evidence linking hypertension to thrombosis and the efficacy of antithrombotic agents.
  • Analysis of current guidelines recommending aspirin 75 mg daily for specific hypertensive patient groups.
  • Consideration of risk-benefit analysis, including bleeding events associated with aspirin.

Main Results:

  • Antihypertensive treatment reduces cardiovascular risk by 25% in hypertensive patients with a 10-year CHD risk ≥ 15%.
  • Adding aspirin further reduces major cardiovascular events by 15% in this group.
  • Guidelines recommend aspirin for secondary prevention and primary prevention in select high-risk hypertensive patients, but bleeding risks are a concern.

Conclusions:

  • Aspirin use is recommended for specific hypertensive patients based on risk stratification and clinical guidelines.
  • The benefits of aspirin in preventing cardiovascular events must be weighed against the increased risk of major bleeding, particularly in lower-risk individuals.

Related Concept Videos

Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Hypertension V: Nursing Management01:23

Hypertension V: Nursing Management

The nursing management of hypertension involves accurately assessing symptoms, making a comprehensive nursing diagnosis, collaborating with patients to set goals, and implementing targeted interventions to mitigate the condition's impact and improve patient well-being.Comprehensive AssessmentThe initial step in nursing care for hypertension involves a thorough patient assessment. It includes evaluating symptoms such as headaches, dizziness, blurred vision, and previous hypertension episodes.
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...